Bortezomib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BORTEZOMIB |
|---|---|
| Type | Drug |
| Aliases | VelcadeБортезоміб |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-MM DIS-WM |
| Sources | SRC-NCCN-MM-2025 |
Drug Facts
| Class | proteasome_inhibitor — boronic-acid 26S proteasome inhibitor |
|---|---|
| Mechanism | Reversibly inhibits the chymotrypsin-like activity of the 26S proteasome, causing accumulation of misfolded proteins and ER-stress-mediated apoptosis in plasma cells, which are uniquely sensitive due to high immunoglobulin synthesis. |
| Typical dosing | 1.3 mg/m² SC days 1, 4, 8, 11 of 21-day cycle (or weekly schedule day 1, 8, 15, 22 of 28-day cycle) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
SC administration strongly preferred over IV — equivalent efficacy with ~half the rate of grade ≥3 peripheral neuropathy. HSV/VZV prophylaxis with acyclovir is mandatory for the duration of therapy.
Used By
Contraindications
CI-BORTEZOMIB-SEVERE-NEUROPATHY- CI-BORTEZOMIB-SEVERE-NEUROPATHY
Regimens
REG-DARA-VRD- Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (D-VRd), 4-6 induction cyclesREG-VRD- Bortezomib + Lenalidomide + Dexamethasone (VRd), 4-6 induction cyclesREG-VRD-LITE- VRd-lite (Bortezomib + Lenalidomide + Dexamethasone, attenuated for elderly/frail MM)REG-VRD-WM- Bortezomib + Rituximab + Dexamethasone (BDR) × 6-8 cycles — chemo-free alternative for r/...